Sonnet BioTherapeutics Holdings Profit Margin

Sonnet BioTherapeutics Holdings (SONN) currently reports a profit margin of -16.11% as of September 2025. That compares with -81.77% in the prior-year period — down 1870.5% year over year. That is below the Consumer Staples sector average of 14.42%. Use the charts on this page to explore Sonnet BioTherapeutics Holdings's profit margin history and peer comparisons.

Sonnet BioTherapeutics Holdings's profit margin decreased from -81.77% to -16.11% — a 1870.5% year-over-year decrease (period ending September 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Sonnet BioTherapeutics Holdings's profit margin of -16.11% is lower than the Consumer Staples sector average of 14.42%. That is roughly 11270.1% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Sonnet BioTherapeutics Holdings's current -16.11% should be judged against Consumer Staples norms (sector average: 14.42%) and against SONN's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -16.11%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Consumer Staples average is 14.42%. From there, open related valuation or income-statement pages for Sonnet BioTherapeutics Holdings, and consider following SONN for alerts when major investors trade the stock.